Genetically engineered immune cells wipe out lupus in mice
By Jennifer Couzin-FrankelMar. 6, 2019 , 2:00 PM
Lupus can be a stubborn disease to treat. Although many struck by the autoimmune condition live relatively normal lives, some suffer from kidney failure, blood clots, and other complications that can be deadly. Now, scientists have found that a novel treatment that wipes out the immune system’s B cells cures mice of the condition. Though the work is preliminary, it has excited researchers because it uses a therapy already approved for people with blood cancer.
“This is a critical stepping stone,” says Jennifer Anolik, a rheumatologist who runs the lupus clinic at the University of Rochester Medical Center in New York who was not involved with the work.
The strategy is known as chimeric antigen receptor (CAR)-T therapy. It involves genetically engineering T cells, the sentries of the immune system, so they recognize and destroy certain cells in the body. Although it comes with potentially serious side effects, it can be lifesaving. The approach took the cancer world by storm in 2011, after scientists reported saving patients with an advanced form of leukemia. Since then, it has been approved to treat certain leukemias in children and lymphomas in adults. Although CAR-T therapy can target different cells, the approved treatments hunt down and destroy B cells by spotting a protein marker, CD19, that almost all B cells sport on their surface.
SIGN UP FOR OUR DAILY NEWSLETTER
Get more great content like this delivered right to you!
Since CAR-T therapy emerged, scientists who study autoimmune diseases have eyed it with interest because B cells are involved in many of these diseases. B cells can release autoantibodies that damage the body’s tissue and provoke T cells into attacks on tissues as well. In 2016, a team at the University of Pennsylvania reported that mice with a rare autoimmune disease called pemphigus vulgaris were helped by CAR-T therapy.
But lupus has presented a puzzle. An antibody called rituximab, which depletes B cells and is often prescribed to patients with rheumatoid arthritis and multiple sclerosis, failed to help many people with lupus in two large clinical trials. That “caused a bit of head-scratching,” says Marko Radic, an immunologist at the University of Tennessee Health Science Center in Memphis.
Did the results mean B cells weren’t important in lupus after all? The answer is no, suggests Mark Shlomchik, an immunologist at the University of Pittsburgh in Pennsylvania who was not involved in the new study. He believes rituximab stumbled in part because of an unfortunate confluence of how the antibody works and how the immune system falters in lupus. Rituximab needs immune cells called macrophages to step in and assist in B cell destruction. That works in some diseases, but in lupus, those cells can be “paralyzed,” says Shlomchik, and struggle to pull this off.
Enter CAR-T therapy, where T cells become efficient B cell slayers without needing a helping hand. Radic and his colleagues tested the approach in two mouse models of lupus. After the mice got sick, the team exposed them to whole-body radiation to wipe out existing immune cells. (People getting CAR-T therapy receive chemotherapy for the same purpose.) Then, the scientists infused the genetically altered T cells into 41 animals.
In 26 of the mice, the CAR-T cells successfully destroyed the B cells with CD19—nearly all of them—and those cells never reappeared. That’s similar to what’s been observed in cancer patients who undergo CAR-T therapy. The effects on mouse health surprised even Radic, who’d had high hopes: The animals’ spleens, skin, kidneys, and other body parts showed no remaining signs of lupus, the team reports today in Science Translational Medicine. “We were so impressed,” Radic says.
Most of the animals that were successfully treated lived for more than a year after treatment, a long stretch in mouse-time. Animals that got placebo therapy all died within 8 to 10 months, and many perished earlier.
Anolik says she would like to better understand why CAR-T therapy didn’t work for 15 mice. But she’s hopeful for the treatment’s future for her patients and others.
The findings are “very compelling,” Shlomchik says. In some patients, lupus is “as aggressive as cancer,” he says, so even a drastic treatment could make sense.Posted in:
More from News
- Measles may have emerged when large cities rose, 1500 years earlier than thought
- Polio eradication program faces hard choices as endgame strategy falters
- ‘Polygenic’ profile could better predict disease risk for those with cancer mutations
Got a tip?
- Chinese scientist who produced genetically altered babies sentenced to 3 years in jailBY DENNIS NORMILEDEC. 30, 2019
- Trump’s NSF pick reflects close links between agency and White HouseBY JEFFREY MERVISDEC. 23, 2019
- Bullying allegations lead to firing of prominent ancient DNA expertBY MEREDITH WADMANDEC. 20, 2019
- Relocated island wolves outlasting mainland wolves in new Isle Royale homeBY CHRISTINE MLOTDEC. 20, 2019
- 2020 U.S. spending bill restricts some animal research, pushes for lab animal retirementBY DAVID GRIMMDEC. 19, 2019
- Watch a puffin use a tool—to scratch an itchBY EVA FREDERICKDEC. 30, 2019
- U.S. West Coast waters are acidifying twice as fast as global averageBY EVA FREDERICKDEC. 18, 2019
- Scientists hope to fight antibiotic-resistant bacteria by targeting their ‘alarm proteins’BY EVA FREDERICKDEC. 10, 2019
- Scientists just found a planet circling a dead starBY EVA FREDERICKDEC. 5, 2019
- Rising temperatures may be making birds smallerBY EVA FREDERICKDEC. 4, 2019
20 December 2019
Vol 366, Issue 6472
- SCIENTIFIC COMMUNITYRude reviews are pervasive and sometimes harmful, study finds
- SCIENTIFIC COMMUNITYTwo Asian American women allege bias by HHMI
- MEDICINE/DISEASES‘Polygenic’ analyses may sharpen disease risk predictions
- SCIENTIFIC COMMUNITYTo help the ‘disadvantaged,’ NIH refines its definition
- SCIENTIFIC COMMUNITYNIH director pledges action on harassment after report
- SCIENTIFIC COMMUNITYU.S. takes aim at foreign influence
Get Our E-Alerts
Receive emails from Science. See full listScience Table of ContentsScience Daily NewsWeekly News RoundupScience Editor’s ChoiceFirst Release NotificationScience Careers Job SeekerCountryCountry*AfghanistanAland IslandsAlbaniaAlgeriaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBolivia, Plurinational State ofBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo, The Democratic Republic of theCook IslandsCosta RicaCote D’IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and Mcdonald IslandsHoly See (Vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic ofIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People’s Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People’s Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedonia, The Former Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMartiniqueMauritaniaMauritiusMayotteMexicoMoldova, Republic ofMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorwayOmanPakistanPalestinianPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalQatarReunionRomaniaRussian FederationRWANDASaint Barthélemy Saint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin (French part)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuela, Bolivarian Republic ofVietnamVirgin Islands, BritishWallis and FutunaWestern SaharaYemenZambiaZimbabwe
Email I agree to receive emails from AAAS/Science
and Science advertisers, including information on
products, services, and special offers which may
include but are not limited to news, career
information, & upcoming events.Sign up today
Required fields are indicated by an asterisk (*)
- About Us
- For Advertisers
- For Authors
- For Librarians
- Related Sites
- Stay Connected